Online inquiry

IVTScrip™ mRNA-Human AP2A2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK21580MR)

This product GTTS-WK21580MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AP2A2 protein. This product can be used in Multilymphoid progenitor cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001242837.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 161
UniProt ID O94973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AP2A2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK21580MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28553MR IVTScrip™ mRNA-Human AQP9, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AQP9
GTTS-WK27626MR IVTScrip™ mRNA-Human APOBR, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APOBR
GTTS-WK14529MR IVTScrip™ mRNA-Human ALMS1, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALMS1
GTTS-WK26681MR IVTScrip™ mRNA-Human ATP13A4, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ATP13A4
GTTS-WK10536MR IVTScrip™ mRNA-Human ABCA9, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABCA9
GTTS-WK28535MR IVTScrip™ mRNA-Human APOL3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APOL3
GTTS-WK14130MR IVTScrip™ mRNA-Human ABCA17P, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABCA17P
GTTS-WK17083MR IVTScrip™ mRNA-Human AP2M1, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AP2M1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW